Nuvalent · pitchdeck
Nuvalent | Investor Presentation Deck | 52 slides
52 pages · 4 arc beats · 2 loops
Nuvalent | Investor Presentation Deck | 52 slides
Nuvalent · 2023-11 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1246810121416182022242628303234363840424446485052
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 15 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits — 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits — 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides — 0/1 slides
Market Sizing 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits — 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Traction 12 slides 100% 12/12 slides 100% 12/12 slides · 54 hits — 0/12 slides
25% 3/12 slides 16.7% 2/12 slides 100% 12/12 slides — 0/12 slides
Slide inventory
52 every slide · same image gating as the playbook
03
The slide uses a visual bracket system to connect the core mission statement to three pillars.inspire_vision
04
The slide combines a pipeline status update with a corporate vision statement.summarize
05
Includes a grid of headshots for the leadership team and lists for board members and advisors.other
06
Uses a Venn diagram to illustrate the intersection of solving for resistance and selectivity.present_solution
Open slide detailBeat · Solution
07
Uses a visual process flow to contrast standard therapy failure with Nuvalent's mechanism.frame_problem
08
Uses a visual comparison framework to illustrate the mechanism of action and clinical benefit.present_solution
Open slide detailLoop · Cost Of Inaction
10
The table highlights the clinical gap in patients with prior kinase inhibitor treatment, specifically those with G2032R mutations.size_opportunity
11
The table uses a green/white color coding to highlight positive attributes (Yes) versus negative ones (No).compare_peers
Open slide detailLoop · Cost Of Inaction
12
The slide uses a medical illustration to map specific TRK receptor inhibition side effects to anatomical locations.frame_problem
Open slide detailLoop · Cost Of Inaction
13
The slide uses dot plots for IC50 values and a bar chart for tumor regression, highlighting NVL-520's performance.show_traction
Open slide detailBeat · Traction
14
The slide uses a bar chart to show brain penetrance and a grouped bar chart to show selectivity index, highlighting the drug's potential to avoid off-target CNSpresent_solution
Open slide detailBeat · Traction
15
The slide uses a side-by-side comparison layout to distinguish between the dose escalation (Phase 1) and the registrational intent (Phase 2) study designs.plan_implementation
Open slide detailBeat · Traction
16
The slide details the transition from the all-treated population to the NSCLC response-evaluable population.analyze_data
Open slide detailBeat · Traction
17
The table highlights a heavily pretreated population, with 77% having received 3 or more prior lines of therapy and 71% having received 2 or more prior ROS1 TKIanalyze_data
Open slide detailBeat · Traction
19
The chart displays dose-dependent exposure levels exceeding multiple efficacy thresholds for ROS1 variants in CNS and peripheral tissues.analyze_data
Open slide detailBeat · Traction
20
Clinical trial data table showing efficacy metrics for NVL-520 in NSCLC patients.show_traction
Open slide detailBeat · Traction
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.show_traction
Open slide detailBeat · Traction
22
The chart is a swimmer plot, commonly used in oncology to visualize time-to-event data for individual patients.show_traction
Open slide detailBeat · Traction
23
Includes a spider plot (target lesion change) and a bar chart (allele clearance).show_traction
Open slide detailBeat · Traction
24
Includes specific patient case study (65-year-old female) and aggregate clinical trial data.show_traction
Open slide detailBeat · Traction
25
The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.illustrate_case
27
The slide uses a process flow to show the evolution of data from preliminary Phase 1 to updated data shared with the FDA.present_solution
28
Includes detailed clinical trial design, cohort definitions, and study objectives.show_traction
29
The TPP is presented as a list of key product attributes.present_solution
Open slide detailLoop · Jobs To Be Done
30
The slide uses a structured table to segment the patient population based on treatment history and specific genetic mutations.size_opportunity
Open slide detailLoop · Jobs To Be Done
31
The table highlights NVL-655's superior profile in G1202R and GRLM/GRGA/GRLF activity compared to existing therapies.compare_peers
Open slide detailLoop · Jobs To Be Done
32
Shows superior potency and efficacy against resistant mutations compared to standard-of-care inhibitors like Lorlatinib.show_traction
Open slide detailLoop · Jobs To Be Done
33
The slide uses a bar chart for brain penetrance and a scatter plot for selectivity index to demonstrate the drug's therapeutic profile.present_solution
Open slide detailLoop · Jobs To Be Done
34
Clinical trial design slide detailing patient population, objectives, and cohort structure.present_framework
Open slide detailLoop · Jobs To Be Done
35
BOIN stands for Bayesian Optimal Interval design.analyze_data
Open slide detailLoop · Jobs To Be Done
37
Data cut-off: 8 Aug 2023. Includes detailed footnotes regarding specific patient events.analyze_data
Open slide detailLoop · Jobs To Be Done
38
The chart displays a line graph with error bars representing standard deviation for five different dosage cohorts (15mg to 150mg QD).show_traction
Open slide detailLoop · Jobs To Be Done
39
The chart displays patient-level data categorized by dose and mutation type, highlighting the efficacy of NVL-655 in clearing specific ALK resistance mutations.show_traction
Open slide detailLoop · Jobs To Be Done
40
Data cut-off: 8 Aug 2023. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.show_traction
Open slide detailLoop · Jobs To Be Done
41
The slide uses a split waterfall plot to compare two patient cohorts. It includes a detailed data table below the chart showing dose levels and prior treatment show_traction
42
The chart is a swimmer plot, commonly used in oncology clinical trials to visualize time-to-event data.show_traction
43
The slide presents two patient case studies with MRI scans showing tumor reduction.show_traction
44
Includes clinical data points for EML4-ALK v3, G1202R, G1269A, and I1322M.illustrate_case
45
The slide summarizes clinical trial conclusions for a pharmaceutical asset.summarize
46
The slide uses a Target Product Profile (TPP) framework to define the drug's clinical value proposition.present_solution
47
The slide uses three distinct chart types to demonstrate efficacy, selectivity, and pharmacokinetics.present_solution
49
The slide uses a hexagonal process flow diagram to illustrate the company's R&D strategy.present_solution
50
The slide uses a Gantt-chart style visualization to show the progress of three specific drug candidates (NVL-520, NVL-655, NVL-330) through clinical developmentplan_implementation